LSV Asset Management Raises Position in Elevance Health, Inc. $ELV

LSV Asset Management raised its holdings in Elevance Health, Inc. (NYSE:ELV) by 464.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 46,664 shares of the company’s stock after acquiring an additional 38,400 shares during the quarter. LSV Asset Management’s holdings in Elevance Health were worth $16,358,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Physician Wealth Advisors Inc. lifted its position in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares during the last quarter. Rossby Financial LCC raised its stake in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares in the last quarter. Activest Wealth Management increased its stake in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares during the period. ORG Partners LLC increased its stake in Elevance Health by 120.4% in the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after purchasing an additional 59 shares during the period. Finally, Dorato Capital Management acquired a new position in shares of Elevance Health during the fourth quarter worth about $41,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Stock Down 0.1%

ELV stock opened at $394.41 on Tuesday. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $408.00. The firm’s 50-day simple moving average is $335.93 and its 200 day simple moving average is $336.96. The stock has a market cap of $85.65 billion, a PE ratio of 16.78, a price-to-earnings-growth ratio of 2.23 and a beta of 0.66.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter last year, the company earned $11.97 EPS. Elevance Health’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, sell-side analysts predict that Elevance Health, Inc. will post 26.91 EPS for the current year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. UBS Group boosted their price objective on shares of Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Deutsche Bank Aktiengesellschaft raised shares of Elevance Health from a “hold” rating to a “buy” rating and upped their price target for the stock from $363.00 to $498.00 in a research report on Wednesday, May 20th. The Goldman Sachs Group upped their price target on shares of Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Finally, Guggenheim increased their price objective on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $399.32.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.